Literature DB >> 8333005

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.

E Spina1, A M Pollicino, A Avenoso, G M Campo, E Perucca, A P Caputi.   

Abstract

The effect of the selective serotonin reuptake inhibitor fluvoxamine (100 mg/day for 10 consecutive days) on the kinetics of a single oral dose of imipramine (50 mg) and desipramine (100 mg) was investigated in 12 healthy subjects. Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001). No significant changes in desipramine kinetics were observed during fluvoxamine treatment. These findings indicate that, at the dosage tested, fluvoxamine markedly inhibits the demethylation of imipramine without affecting significantly the CYP2D6-mediated hydroxylation of desipramine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333005     DOI: 10.1097/00007691-199306000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  29 in total

1.  Non-linear fluvoxamine disposition.

Authors:  O Spigset; K Granberg; S Hägg; E Söderström; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.

Authors:  Junichi Azuma; Tomoko Hasunuma; Masanori Kubo; Masaya Miyatake; Toshiko Koue; Koushi Higashi; Tsutomu Fujiwara; Sachiko Kitahara; Tamiki Katano; Sumiko Hara
Journal:  Eur J Clin Pharmacol       Date:  2011-07-08       Impact factor: 2.953

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

6.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

Review 7.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

8.  A case of risperidone overdose in early schizophrenia: a review of potential complications.

Authors:  L C Kopala; C Day; B Dillman; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1998-11       Impact factor: 6.186

9.  Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.

Authors:  Kari Laine; Steven De Bruyn; Harry Björklund; Juha Rouru; Jutta Hänninen; Harry Scheinin; Markku Anttila
Journal:  Eur J Clin Pharmacol       Date:  2004-01-17       Impact factor: 2.953

Review 10.  Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

Authors:  L Ereshefsky; C Riesenman; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.